

Ibrahim Celalettin Haznedaroğlu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1450945/publications.pdf>

Version: 2024-02-01

370
papers

6,456
citations

94433

37
h-index

110387

64
g-index

376
all docs

376
docs citations

376
times ranked

6435
citing authors

#	ARTICLE	IF	CITATIONS
1	The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. <i>Blood</i> , 2013, 121, 4439-4442.	1.4	546
2	Acute graft-vs-host disease Pathobiology and management. <i>Experimental Hematology</i> , 2001, 29, 259-277.	0.4	307
3	Haemostatic Actions of the Folkloric Medicinal Plant Extract Ankaferd Blood Stopper®. <i>Journal of International Medical Research</i> , 2008, 36, 163-170.	1.0	256
4	Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study. <i>Blood</i> , 2009, 113, 4497-4504.	1.4	173
5	The effects of blood group types on the risk of COVID-19 infection and its clinical outcome. <i>Turkish Journal of Medical Sciences</i> , 2020, 50, 679-683.	0.9	139
6	Global Fibrinolytic Capacity Is Decreased in Polycystic Ovary Syndrome, Suggesting a Prothrombotic State. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 3871-3875.	3.6	118
7	Pathological haemostasis and "prothrombotic state"™ in Behçet's disease. <i>Thrombosis Research</i> , 2002, 105, 125-133.	1.7	107
8	Towards the understanding of the local hematopoietic bone marrow renin-angiotensin system. <i>International Journal of Biochemistry and Cell Biology</i> , 2003, 35, 867-880.	2.8	104
9	Endoscopic Application of Ankaferd Blood Stopper as a Novel Experimental Treatment Modality for Upper Gastrointestinal Bleeding: A Case Report. <i>American Journal of Gastroenterology</i> , 2008, 103, 2156-2158.	0.4	90
10	Hemostatic Efficacy of Ankaferd Blood Stopper® in a Swine Bleeding Model. <i>Medical Principles and Practice</i> , 2009, 18, 165-169.	2.4	76
11	Endoscopic topical application of Ankaferd Blood Stopper for neoplastic gastrointestinal bleeding: A retrospective analysis. <i>Digestive and Liver Disease</i> , 2010, 42, 196-199.	0.9	73
12	In Vivo Hemostatic Effect of the Medicinal Plant Extract Ankaferd Blood Stopper in Rats Pretreated With Warfarin. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2009, 15, 270-276.	1.7	69
13	Plateletcrit and red cell distribution width are independent predictors of the slow coronary flow phenomenon. <i>Journal of Cardiology</i> , 2014, 63, 112-118.	1.9	68
14	Effects of oral cyclophosphamide and prednisolone therapy on the endothelial functions and clinical findings in patients with early diffuse systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2003, 48, 2256-2261.	6.7	66
15	A local renin-angiotensin system in the bone marrow. <i>Medical Hypotheses</i> , 1996, 46, 507-510.	1.5	63
16	Pleiotropic cellular, hemostatic, and biological actions of Ankaferd hemostat. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 83, 21-34.	4.4	63
17	Iron deficiency can cause cognitive impairment in geriatric patients. <i>Journal of Nutrition, Health and Aging</i> , 2012, 16, 220-224.	3.3	61
18	Successful Management of Bleeding Due to Solitary Rectal Ulcer via Topical Application of Ankaferd Blood Stopper. <i>Journal of Alternative and Complementary Medicine</i> , 2008, 14, 1073-1074.	2.1	60

#	ARTICLE	IF	CITATIONS
19	Ultrastructural and Morphological Analyses of the In Vitro and In Vivo Hemostatic Effects of Ankaferd Blood Stopper. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2010, 16, 446-453.	1.7	56
20	Pathologic thrombopoiesis of rheumatoid arthritis. <i>Rheumatology International</i> , 2003, 23, 49-60.	3.0	54
21	Perianal infections in patients with leukemia. <i>Diseases of the Colon and Rectum</i> , 1998, 41, 81-85.	1.3	53
22	Convalescent plasma therapy in patients with COVID-19. <i>Transfusion and Apheresis Science</i> , 2021, 60, 102955.	1.0	52
23	Review: Pathobiological aspects of the local bone marrow renin-angiotensin system: a review. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2010, 11, 205-213.	1.7	50
24	Evaluation of hemostatic effects of Ankaferd as an alternative medicine. <i>Alternative Medicine Review</i> , 2010, 15, 329-36.	3.3	50
25	Rethinking leptin and insulin action: Therapeutic opportunities for diabetes. <i>International Journal of Biochemistry and Cell Biology</i> , 2006, 38, 820-830.	2.8	49
26	The efficacy of Ankaferd Blood Stopper in antithrombotic drug-induced primary and secondary hemostatic abnormalities of a rat-bleeding model. <i>Blood Coagulation and Fibrinolysis</i> , 2009, 20, 185-190.	1.0	48
27	Circulating Thrombomodulin as a Clue of Endothelial Damage in Behçet's Disease. <i>Thrombosis and Haemostasis</i> , 1996, 75, 974-975.	3.4	48
28	Old antihypertensives as novel antineoplastics: angiotensin-I-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists. <i>Medical Hypotheses</i> , 2002, 59, 344-348.	1.5	46
29	Ankaferd Blood Stopper for Controlling Gastrointestinal Bleeding due to Distinct Benign Lesions Refractory to Conventional Antihemorrhagic Measures. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2010, 24, 380-384.	1.7	45
30	Plateletcrit. <i>Herz</i> , 2014, 39, 142-148.	1.1	45
31	Tandem oral, rectal, and nasal administrations of Ankaferd Blood Stopper to control profuse bleeding leading to hemodynamic instability. <i>American Journal of Emergency Medicine</i> , 2009, 27, 631.e1-631.e2.	1.6	43
32	Topical Ankaferd Blood Stopper Administration to Bleeding Gastrointestinal Carcinomas Decreases Tumor Vascularization. <i>American Journal of Gastroenterology</i> , 2009, 104, 2874-2877.	0.4	42
33	Convalescent (immune) plasma treatment in a myelodysplastic COVID-19 patient with disseminated tuberculosis. <i>Transfusion and Apheresis Science</i> , 2020, 59, 102821.	1.0	42
34	Ankaferd hemostat in the management of gastrointestinal hemorrhages. <i>World Journal of Gastroenterology</i> , 2011, 17, 3962.	3.3	41
35	Local bone marrow renin-angiotensin system in primitive, definitive and neoplastic haematopoiesis. <i>Clinical Science</i> , 2013, 124, 307-323.	4.3	41
36	Renin and angiotensin-converting enzyme (ACE) as active components of the local synovial renin-angiotensin system in rheumatoid arthritis. <i>Rheumatology International</i> , 2005, 25, 285-291.	3.0	40

#	ARTICLE	IF	CITATIONS
37	Increased plasma levels of soluble selectins in patients with unstable angina. <i>International Journal of Cardiology</i> , 2001, 78, 69-73.	1.7	38
38	Functional proteomic analysis of Ankaferd® Blood Stopper. <i>Turkish Journal of Haematology</i> , 2010, 27, 70-77.	0.5	38
39	Oral Systemic Administration of Ankaferd Blood Stopper Has No Short-Term Toxicity in an In Vivo Rabbit Experimental Model. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2010, 16, 533-536.	1.7	38
40	Two common genetic thrombotic risk factors: Factor V Leiden and prothrombin G20210A in adult Turkish patients with thrombosis. <i>American Journal of Hematology</i> , 2001, 67, 107-111.	4.1	37
41	Soy protein diet significantly improves endothelial function and lipid parameters. <i>Clinical Cardiology</i> , 2001, 24, 711-716.	1.8	37
42	Effects of interferon- γ 2a treatment on serum levels of tumor necrosis factor- α , tumor necrosis factor- β 2 receptor, interleukin-2, interleukin-2 receptor, and E-selectin in Behçet's disease. <i>Rheumatology International</i> , 1999, 19, 11-14.	3.0	36
43	Rational use of the PFA-100 device for screening of platelet function disorders and von Willebrand disease. <i>Blood Coagulation and Fibrinolysis</i> , 2002, 13, 349-353.	1.0	36
44	Clinical associations, biological risk factors and outcomes of cerebral venous sinus thrombosis. <i>Journal of International Medical Research</i> , 2016, 44, 1454-1461.	1.0	35
45	Over-expression of angiotensin-converting enzyme (CD 143) on leukemic blasts as a clue for the activated local bone marrow RAS in AML. <i>Leukemia and Lymphoma</i> , 2006, 47, 891-896.	1.3	34
46	Phospholipase A2 activity in platelets of patients with uremia. <i>Platelets</i> , 2002, 13, 415-418.	2.3	33
47	Circulating and Local Bone Marrow Renin-angiotensin System in Leukemic Hematopoiesis: Preliminary Evidences. <i>Hematology</i> , 2002, 7, 75-82.	1.5	33
48	MPV may reflect subclinical platelet activation in diabetic patients with and without diabetic retinopathy. <i>Eye</i> , 2015, 29, 376-379.	2.1	33
49	Megakaryocyte-Related Interleukins in Reactive Thrombocytosis versus Autonomous Thrombocythemia. <i>Acta Haematologica</i> , 1996, 95, 107-111.	1.4	32
50	Effects of short-term atorvastatin treatment on global fibrinolytic capacity, and sL-selectin and sFas levels in hyperlipidemic patients with coronary artery disease. <i>International Journal of Cardiology</i> , 2002, 84, 227-231.	1.7	32
51	Tamoxifen-induced tissue factor pathway inhibitor reduction: a clue for an acquired thrombophilic state?. <i>Annals of Oncology</i> , 2004, 15, 1622-1626.	1.2	32
52	How hematopoietic stem cells know and act in cardiac microenvironment for stem cell plasticity? Impact of local renin-angiotensin systems. <i>Medical Hypotheses</i> , 2004, 63, 866-874.	1.5	31
53	Increased mean platelet volume (MPV) indicating the vascular risk in Alzheimer's disease (AD). <i>Archives of Gerontology and Geriatrics</i> , 2012, 55, 257-260.	3.0	31
54	EUTOS CML prognostic scoring system predicts ELN-based "event-free survival"™ better than Euro/Hasford and Sokal systems in CML patients receiving front-line imatinib mesylate. <i>Hematology</i> , 2013, 18, 247-252.	1.5	31

#	ARTICLE	IF	CITATIONS
55	Activation of Blood Coagulation in Patients With Mitral Stenosis and Sinus Rhythm. American Journal of Cardiology, 1998, 81, 795-797.	1.6	29
56	Overexpression of the local bone marrow renin-angiotensin system in acute myeloid leukemia. Journal of the National Medical Association, 2007, 99, 57-63.	0.8	28
57	In vivo platelet and T-lymphocyte activities during pulmonary tuberculosis. European Respiratory Journal, 1998, 12, 1375-1379.	6.7	27
58	Angiotensin-converting enzyme gene polymorphism in Behçet's disease. Clinical Rheumatology, 2004, 23, 142-146.	2.2	27
59	Current concerns of undertreatment and overtreatment in chronic myeloid leukemia based on European LeukemiaNet 2013 recommendations. Expert Opinion on Pharmacotherapy, 2013, 14, 2005-2010.	1.8	27
60	Cytokines affecting megakaryocytopoiesis in rheumatoid arthritis with thrombocytosis. Rheumatology International, 1996, 16, 5-8.	3.0	26
61	Assessment of Autonomic Nervous System Functions in Patients with Vitamin B12 Deficiency by Power Spectral Analysis of Heart Rate Variability. PACE - Pacing and Clinical Electrophysiology, 2000, 23, 975-978.	1.2	26
62	Upper Gastrointestinal Bleeding in a Patient With Defective Hemostasis Successfully Treated with Ankaferd Blood Stopper. Phytotherapy Research, 2011, 25, 312-313.	5.8	26
63	Thrombocytopenia Complicating the Clinical Course of Leptospiral Infection. Journal of International Medical Research, 2002, 30, 535-540.	1.0	25
64	Thrombopoietin as a Drug: Biologic Expectations, Clinical Realities, and Future Directions. Clinical and Applied Thrombosis/Hemostasis, 2002, 8, 193-212.	1.7	25
65	Patients with paroxysmal atrial fibrillation but not paroxysmal supraventricular tachycardia display evidence of platelet activation during arrhythmia. Platelets, 2003, 14, 407-411.	2.3	25
66	Fenofibrate improves endothelial function and decreases thrombin-activatable fibrinolysis inhibitor concentration in metabolic syndrome. Blood Coagulation and Fibrinolysis, 2008, 19, 310-314.	1.0	25
67	Local umbilical cord blood renin-angiotensin system. Annals of Hematology, 2005, 84, 277-281.	1.8	24
68	Overt gastrointestinal bleeding in haematologic neoplasms. Digestive and Liver Disease, 2005, 37, 917-922.	0.9	24
69	Endobronchial application of Ankaferd blood stopper to control profuse lung bleeding leading to hypoxemia and hemodynamic instability. Respiratory Medicine CME, 2009, 2, 144-146.	0.1	24
70	The effects of Ankaferd Blood Stopper on transcription factors in HUVEC and erythrocyte protein profile. Turkish Journal of Haematology, 2011, 28, 276-85.	0.5	24
71	Beneficial effects of Ankaferd Blood Stopper on caustic esophageal injuries: an experimental model. Ecological Management and Restoration, 2012, 25, 188-194.	0.4	24
72	Serum L-selectin and P-selectin levels in lymphomas. Haematologia, 2000, 30, 27-30.	0.3	23

#	ARTICLE	IF	CITATIONS
73	Hemostatic parameters in Behçet's disease: a reappraisal. <i>Rheumatology International</i> , 2002, 22, 9-15.	3.0	22
74	Prohemostatic and Antithrombin Activities of Ankaferd Hemostat Are Linked to Fibrinogen Gamma Chain and Prothrombin by Functional Proteomic Analyses. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2012, 18, 604-610.	1.7	22
75	Hyper-CVAD Regimen in Routine Management of Adult Acute Lymphoblastic Leukemia: A Retrospective Multicenter Study. <i>Acta Haematologica</i> , 2013, 130, 199-205.	1.4	22
76	Current perspectives for the treatment of chronic myeloid leukemia. <i>Turkish Journal of Medical Sciences</i> , 2019, 49, 1-10.	0.9	21
77	Activated protein C resistance in Behçet's disease. <i>Rheumatology International</i> , 1998, 17, 249-250.	3.0	20
78	Haemostasis, Thrombosis, and Endothelium in Behcet's Disease. <i>Acta Haematologica</i> , 1998, 99, 236-237.	1.4	20
79	Cardiac and Great Vessel Thrombosis in Behcet's Disease.. <i>Internal Medicine</i> , 2001, 40, 68-72.	0.7	20
80	Changes in the concentration and distribution of tissue factor pathway inhibitor in Behcet's disease and systemic lupus erythematosus: effect on the prethrombotic state. <i>Annals of the Rheumatic Diseases</i> , 2001, 60, 1149-1151.	0.9	20
81	Evaluation of the Impact of Treatment on Endothelial Function and Cardiac Performance in Acromegaly. <i>Echocardiography</i> , 2010, 27, 990-996.	0.9	20
82	A new practical alternative for tumoural gastrointestinal bleeding: Ankaferd blood stopper. <i>Digestive and Liver Disease</i> , 2010, 42, 594-595.	0.9	20
83	Increased ferritin levels could reflect ongoing aging-associated inflammation and may obscure underlying iron deficiency in the geriatric population. <i>European Geriatric Medicine</i> , 2012, 3, 277-280.	2.8	20
84	Human Ace D/I Polymorphism Could Affect the Clinicobiological Course of COVID-19. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2021, 2021, 1-7.	1.7	20
85	Eicosanoids in the prethrombotic state of Behçet's disease. <i>Thrombosis Research</i> , 1995, 80, 445-446.	1.7	19
86	The Search for a Common Thrombophilic State During the Active State of Inflammatory Bowel Disease. <i>Journal of Clinical Gastroenterology</i> , 2006, 40, 809-813.	2.2	19
87	Spontaneous tumor lysis syndrome in a patient with diffuse large B cell lymphoma and Richter syndrome. <i>Annals of Hematology</i> , 2006, 85, 183-184.	1.8	19
88	The factors affecting early death in newly diagnosed APL patients. <i>Open Medicine (Poland)</i> , 2019, 14, 647-652.	1.3	19
89	Antimicrobial activity of Ankaferd Blood Stopper® against nosocomial bacterial pathogens. <i>Open Medicine (Poland)</i> , 2010, 5, 198-202.	1.3	18
90	Increased ACE in extrahepatic cholangiocarcinoma as a clue for activated RAS in biliary neoplasms. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2011, 35, 644-649.	1.5	18

#	ARTICLE	IF	CITATIONS
91	Renin angiotensin system genes are biomarkers for personalized treatment of acute myeloid leukemia with Doxorubicin as well as etoposide. PLoS ONE, 2020, 15, e0242497.	2.5	18
92	Acute tumor lysis syndrome associated with paclitaxel. Annals of Pharmacotherapy, 1997, 31, 1548-1549.	1.9	17
93	Current Debates in Antiphospholipid Syndrome: The Acquired Antibody-Mediated Thrombophilia. Clinical and Applied Thrombosis/Hemostasis, 2004, 10, 89-126.	1.7	17
94	Plasma Soluble Osteopontin Concentrations Are Increased in Patients With Rheumatic Mitral Stenosis and Associated With the Severity of Mitral Valve Calcium. American Journal of Cardiology, 2006, 98, 817-820.	1.6	17
95	Warfarin-induced skin necrosis and leukocytoclastic vasculitis in a patient with acquired protein C and protein S deficiency. Blood Coagulation and Fibrinolysis, 2007, 18, 805-806.	1.0	17
96	Effects of Imatinib Mesylate on Renin-Angiotensin System (RAS) Activity during the Clinical Course of Chronic Myeloid Leukaemia. Journal of International Medical Research, 2009, 37, 1018-1028.	1.0	17
97	Clinical features and outcomes of 49 Turkish patients with acute promyelocytic leukemia who received ATRA and anthracyclines (PETHEMA protocol) therapy. Leukemia Research, 2010, 34, e317-e319.	0.8	17
98	Elevated Levels of Circulating Angiotensin Converting Enzyme in Patients with Hepatoportal Sclerosis. Digestive Diseases and Sciences, 2011, 56, 2160-2165.	2.3	17
99	Reversible Protease-Activated Receptor 1 Downregulation Mediated by Ankaferd Blood Stopper Inducible With Lipopolysaccharides Inside the Human Umbilical Vein Endothelial Cells. Clinical and Applied Thrombosis/Hemostasis, 2011, 17, E165-E170.	1.7	17
100	In vivo confocal microscopic characteristics of crystalline keratopathy in patients with monoclonal gammopathy: Report of two cases. Indian Journal of Ophthalmology, 2014, 62, 938.	1.1	17
101	Unchanged global fibrinolytic capacity despite increased factor VIIa activity in Behçet's disease: evidence of a prethrombotic state. Rheumatology International, 2002, 21, 137-140.	3.0	16
102	Successful treatment of rheumatoid arthritis is associated with a reduction in serum sE-selectin and thrombomodulin level. Clinical Rheumatology, 2004, 23, 430-434.	2.2	16
103	Extramedullary plasmacytomas of the thyroid and pericardium as initial presentation of multiple myeloma. Annals of Hematology, 2008, 87, 853-854.	1.8	16
104	Thrombomodulin and GFC levels in Legg-Calve-Perthes disease. Hematology, 2008, 13, 324-328.	1.5	16
105	Evidence for Higher Red Blood Cell Mass in Persons With Unconjugated Hyperbilirubinemia and Gilbert's Syndrome. American Journal of the Medical Sciences, 2008, 335, 115-119.	1.1	16
106	Bleeding due to slippage of elastic band during variceal ligation: successful use of Ankaferd blood stopper. Indian Journal of Gastroenterology, 2010, 29, 166-168.	1.4	16
107	The effect of a new hemostatic agent for difficult cases of non-variceal gastrointestinal bleeding: Ankaferd blood stopper. Hepato-Gastroenterology, 2010, 57, 191-4.	0.5	16
108	Chronic lymphocytic leukemia presenting as acute urinary retention due to leukemic infiltration of the prostate. Annals of Hematology, 1996, 73, 143-144.	1.8	15

#	ARTICLE	IF	CITATIONS
109	Selectins and IL-6 during the Clinical Course of Idiopathic Thrombocytopenic Purpura. <i>Acta Haematologica</i> , 1999, 101, 16-20.	1.4	15
110	Local Bone Marrow Renin-Angiotensin System and Atherosclerosis. <i>Cardiology Research and Practice</i> , 2011, 2011, 1-10.	1.1	15
111	DRUG THERAPY IN THE PROGRESSED CML PATIENT WITH MULTI-TKI FAILURE. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2015, 7, e2015014.	1.3	15
112	Bone marrow fibrosis may be an effective independent predictor of the $\hat{\alpha}$ TKI drug response level $\hat{\alpha}$ ™ in chronic myeloid leukemia. <i>Hematology</i> , 2015, 20, 392-396.	1.5	15
113	Growth inhibitory activity of Ankaferd hemostat on primary melanoma cells and cell lines. <i>SAGE Open Medicine</i> , 2017, 5, 205031211668951.	1.8	15
114	Biphasic effects of ankaferd blood stopper on renal tubular apoptosis in the rat partial nephrectomy model representing distinct levels of hemorrhage. <i>Journal of King Abdulaziz University, Islamic Economics</i> , 2010, 31, 864-8.	1.1	15
115	Megakaryocytopoietic cytokines in autoimmune thrombocytopenic purpura. <i>American Journal of Hematology</i> , 1995, 49, 265-265.	4.1	14
116	Albendazole-Induced Amegakaryocytic Thrombocytopenic Purpura. <i>Annals of Pharmacotherapy</i> , 1998, 32, 842-842.	1.9	14
117	Plasminogen activator inhibitor-1 as a link between pathological fibrinolysis and arthritis of Behçet's disease. <i>Rheumatology International</i> , 2004, 24, 98-102.	3.0	14
118	Systemic toxocariasis presenting with leukemoid reaction and hypereosinophilia. <i>American Journal of Hematology</i> , 2005, 79, 171-171.	4.1	14
119	Spinal Myeloid Sarcoma in Two Non-Leukemic Patients. <i>Internal Medicine</i> , 2010, 49, 2493-2497.	0.7	14
120	Ankaferd Blood Stopper for Gastrointestinal Bleeding. <i>Journal of Investigative Surgery</i> , 2010, 23, 239-239.	1.3	14
121	Increased circulating soluble P-selectin in polycystic ovary syndrome. <i>Fertility and Sterility</i> , 2010, 93, 2311-2315.	1.0	14
122	Identification of clinical and simple laboratory variables predicting responsible gastrointestinal lesions in patients with iron deficiency anemia. <i>International Journal of Medical Sciences</i> , 2011, 8, 30-38.	2.5	14
123	Turkish Chronic Myeloid Leukemia Study: Retrospective Sectional Analysis of CML Patients. <i>Turkish Journal of Haematology</i> , 2013, 30, 351-358.	0.5	14
124	Qualitative/Chemical Analyses of Ankaferd Hemostat and Its Antioxidant Content in Synthetic Gastric Fluids. <i>BioMed Research International</i> , 2016, 2016, 1-8.	1.9	14
125	Circulating Thrombopoietin in Clonal Versus Reactive Thrombocytosis. <i>Hematology</i> , 2002, 7, 9-12.	1.5	13
126	ENHANCED TISSUE FACTOR PATHWAY INHIBITOR RESPONSE AS A DEFENSE MECHANISM AGAINST ONGOING LOCAL MICROVASCULAR EVENTS OF LEGG-CALVE-PERTHES DISEASE. <i>Pediatric Hematology and Oncology</i> , 2005, 22, 391-399.	0.8	13

#	ARTICLE	IF	CITATIONS
127	Renin-angiotensin system expression in the K562 human erythroleukaemic cell line. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2007, 8, 145-147.	1.7	13
128	Severe Arterial Thrombophilia Associated With a Homozygous MTHFR Gene Mutation (A1298C) in a Young Man With Klinefelter Syndrome. Clinical and Applied Thrombosis/Hemostasis, 2008, 14, 369-371.	1.7	13
129	Changes in vascular endothelial growth factor, angiopoietins, and Tie-2 levels with G-CSF stimulation in healthy donors. Annals of Hematology, 2009, 88, 667-671.	1.8	13
130	Successful treatment of endoscopic sphincterotomy-induced early hemorrhage with application of Ankaferd Blood Stopper. Gastrointestinal Endoscopy, 2010, 72, 1325-1326.	1.0	13
131	Pathobiological Interactions of Local Bone Marrow Renin-Angiotensin System and Central Nervous System in Systemic Arterial Hypertension. Frontiers in Endocrinology, 2020, 11, 425.	3.5	13
132	Angiotensin-converting enzyme expression of the lymphoma-associated macrophages in the lymph nodes of Hodgkin's disease. Journal of the National Medical Association, 2007, 99, 1243-4, 1246-7.	0.8	13
133	Serum thrombopoietin levels in haemodialysis patients: involvement of arteriovenous fistula. Nephrology Dialysis Transplantation, 1999, 14, 2173-2177.	0.7	12
134	Increased soluble glycoprotein V concentration during the acute onset of unstable angina pectoris in association with chronic cigarette smoking. Platelets, 2005, 16, 329-333.	2.3	12
135	A new candidate as a hemostatic agent for difficult situations during variceal bleeding: Ankaferd blood stopper. Saudi Journal of Gastroenterology, 2011, 17, 145.	1.1	12
136	Topical Ankaferd hemostat application for the management of oral cavity bleedings in children with hemorrhagic diathesis. Blood Coagulation and Fibrinolysis, 2012, 23, 494-497.	1.0	12
137	MONITORING THE RESPONSE TO TYROSINE KINASE INHIBITOR (TKI) TREATMENT IN CHRONIC MYELOID LEUKEMIA (CML). Mediterranean Journal of Hematology and Infectious Diseases, 2014, 6, e2014009.	1.3	12
138	Rebound Thrombocytosis following Induction Chemotherapy Is an Independent Predictor of a Good Prognosis in Acute Myeloid Leukemia Patients Attaining First Complete Remission. Acta Haematologica, 2015, 134, 32-37.	1.4	12
139	In vitro analysis of the renin-angiotensin system and inflammatory gene transcripts in human bronchial epithelial cells after infection with severe acute respiratory syndrome coronavirus. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2020, 21, 147032032092887.	1.7	12
140	Decreased Protein Z Concentrations Complicating the Hypercoagulable State of Behçet's Disease. Clinical and Applied Thrombosis/Hemostasis, 2003, 9, 259-263.	1.7	11
141	Cytarabine-induced fever complicating the clinical course of leukemia. Anti-Cancer Drugs, 2005, 16, 59-62.	1.4	11
142	Decrements in the Thrombin Activatable Fibrinolysis Inhibitor (TAFI) Levels in Association with Orlistat Treatment in Obesity. Clinical and Applied Thrombosis/Hemostasis, 2006, 12, 364-368.	1.7	11
143	Short-Term Hemostatic Safety of Strontium Ranelate Treatment in Elderly Women with Osteoporosis. Annals of Pharmacotherapy, 2007, 41, 41-45.	1.9	11
144	Association of plasma osteopontin levels with coronary calcification evaluated by tomographic coronary calcium scoring. Journal of Bone and Mineral Metabolism, 2009, 27, 591-597.	2.7	11

#	ARTICLE	IF	CITATIONS
145	Potential biomarkers for vascular damage in Alzheimer's disease: Thrombomodulin and von Willebrand factor. <i>Journal of Nutrition, Health and Aging</i> , 2010, 14, 439-441.	3.3	11
146	Circulating CD4+CD25+ Regulatory T Cells in the Pathobiology of Ulcerative Colitis and Concurrent Primary Sclerosing Cholangitis. <i>Digestive Diseases and Sciences</i> , 2013, 58, 1250-1255.	2.3	11
147	Proteomic and transcriptomic analyses to explain the pleiotropic effects of Ankaferd blood stopper. <i>SAGE Open Medicine</i> , 2017, 5, 205031211772256.	1.8	11
148	Evaluation of the Survival Outcomes of Multiple Myeloma Patients According to Their Plasmacytoma Presentation at Diagnosis. <i>Turkish Journal of Haematology</i> , 2020, 37, 256-262.	0.5	11
149	Imatinib mesylate and the management of chronic myeloid leukemia (CML). <i>Turkish Journal of Haematology</i> , 2005, 22, 161-72.	0.5	11
150	Cytokines, Endothelium, and Adhesive Molecules in Pathologic Thrombopoiesis. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2001, 7, 126-130.	1.7	10
151	The Predictability of Factor V Leiden (FV:Q506) Gene Mutation via Clotting-Based Diagnosis of Activated Protein C Resistance. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2004, 10, 265-270.	1.7	10
152	No alteration in the PFA-100 in vitro bleeding time induced by the Ginkgo biloba special extract, EGb 761, in elderly patients with mild cognitive impairment. <i>Blood Coagulation and Fibrinolysis</i> , 2005, 16, 349-353.	1.0	10
153	Local hematopoietic renin-angiotensin system in myeloid versus lymphoid hematological neoplastic disorders. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2013, 14, 308-314.	1.7	10
154	Multicenter Retrospective Analysis of Turkish Patients with Chronic Myeloproliferative Neoplasms. <i>Turkish Journal of Haematology</i> , 2017, 34, 27-33.	0.5	10
155	Granulocytic Sarcoma in Acute Promyelocytic Leukemia. <i>Leukemia and Lymphoma</i> , 1996, 22, 183-185.	1.3	9
156	Platelet and Leukocyte Deactivation After Intracoronary Stent Placement in Patients Receiving Combined Antiplatelet Therapy. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2001, 7, 116-121.	1.7	9
157	Tumor Lysis Syndrome Associated with Fludarabine Treatment in Chronic Lymphocytic Leukemia. <i>Annals of Pharmacotherapy</i> , 2004, 38, 1319-1320.	1.9	9
158	Unusual extramedullary relapses under imatinib mesylate treatment in chronic myeloid leukemia. <i>American Journal of Hematology</i> , 2005, 79, 79-80.	4.1	9
159	Changing clinical manifestations of a T-peripheral lymphoma: From hypereosinophilic syndrome to questionable Kimura's disease resulting in parotid mass. <i>Leukemia and Lymphoma</i> , 2006, 47, 357-360.	1.3	9
160	Unusual extramedullary recurrences and breast relapse despite hepatic GVHD after allografting in Ph+ ALL. <i>Hematology</i> , 2006, 11, 105-107.	1.5	9
161	Tonsillar abscess formation due to herpes simplex type-1 in a severely immunocompromised stem cell transplant patient with chronic myeloid leukemia. <i>Transplant Infectious Disease</i> , 2006, 8, 166-170.	1.7	9
162	Predicting Chronic Leukaemias from Assessment of Complete Peripheral Blood Counts. <i>Journal of International Medical Research</i> , 2006, 34, 640-647.	1.0	9

#	ARTICLE	IF	CITATIONS
163	Effects of Acute Exercise on Fibrinolysis and Coagulation in Patients With Coronary Artery Disease. <i>International Heart Journal</i> , 2007, 48, 277-285.	1.0	9
164	Alterations in the local umbilical cord blood renin-angiotensin system™ during pre-eclampsia. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2007, 86, 1193-1199.	2.8	9
165	Concomitant renal cell carcinoma and lymphoid malignancies: a case series of five patients and review of the literature. <i>Medical Oncology</i> , 2010, 27, 55-58.	2.5	9
166	Atraumatic Osteonecrosis After Estrogen Replacement Therapy Associated with Low Protein S Level in a Patient with Turner Syndrome. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2010, 16, 599-601.	1.7	9
167	Percutaneous ankaferd injection to in vivo liver tissue in comparison to ethanol in an experimental rat model. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2011, 35, 549-553.	1.5	9
168	Ankaferd Blood Stopper Is More Effective Than Adrenaline Plus Lidocaine and Gelatin Foam in the Treatment of Epistaxis in Rabbits. <i>Current Therapeutic Research</i> , 2011, 72, 185-194.	1.2	9
169	Surgical and histopathological effects of topical Ankaferd hemostat on major arterial vessel injury related to elevated intra-arterial blood pressure. <i>Turkish Journal of Haematology</i> , 2011, 28, 206-212.	0.5	9
170	Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic hematopoietic stem cell transplantation for acute leukemia patients: A single center experience. <i>Transfusion and Apheresis Science</i> , 2013, 49, 590-599.	1.0	9
171	Management of De Novo CML and Imatinib-Induced Acute Rhabdomyolysis With the Second-Generation TKI, Dasatinib. <i>Annals of Pharmacotherapy</i> , 2015, 49, 740-742.	1.9	9
172	Branch retinal vein occlusion associated with platelet activation. <i>Turkish Journal of Medical Sciences</i> , 2019, 49, 283-287.	0.9	9
173	Review on Characteristics and Analytical Methods of Rivaroxaban. <i>Critical Reviews in Analytical Chemistry</i> , 2022, 52, 865-877.	3.5	9
174	Agranulocytosis, Plasmacytosis, and Thrombocytosis Followed by a Leukemoid Reaction Due to Acute Acetaminophen Toxicity. <i>Annals of Pharmacotherapy</i> , 1996, 30, 762-765.	1.9	8
175	MEAN PLATELET VOLUME, PLATELET COUNT AND PLATELET DIMENSIONAL WIDTH DURING HEMODIALYSIS. <i>Thrombosis Research</i> , 1997, 86, 405-408.	1.7	8
176	Aplastic pancytopenia associated with thymoma. <i>Annals of Hematology</i> , 2000, 79, 648-650.	1.8	8
177	Plasma fibronectin- and thrombospondin-adhesive molecules during acute attacks and attack-free periods of familial Mediterranean fever. <i>Rheumatology International</i> , 2001, 20, 217-220.	3.0	8
178	Extent of Coronary Atherosclerosis and Homocysteine Affect Endothelial Markers. <i>Angiology</i> , 2001, 52, 589-596.	1.8	8
179	Diminished Global Fibrinolytic Capacity in Patients With Mitral Valve Prolapse Is Associated With Transient Ischemic Attacks. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2002, 8, 41-44.	1.7	8
180	Immediate Effects of Fluvastatin on Circulating Soluble Endothelial Protein C and Free Tissue Factor Pathway Inhibitor in Acute Coronary Syndromes. <i>Cardiovascular Drugs and Therapy</i> , 2005, 19, 177-181.	2.6	8

#	ARTICLE	IF	CITATIONS
181	The Plasma Levels of Prostanoids and Plasminogen Activator Inhibitor-1 in Primary and Secondary Thrombocytosis. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2005, 11, 197-201.	1.7	8
182	Endogenous thrombopoietin levels during the clinical management of acute myeloid leukaemia. <i>Platelets</i> , 2005, 16, 31-37.	2.3	8
183	Multiple Bulky Cutaneous Plasmacytomas with CNS Relapse without Bone Marrow Involvement during the Course of a Lambda Light Chain Myeloma. <i>Onkologie</i> , 2009, 32, 662-664.	0.8	8
184	Serum Stem Cell Factor Level in Renal Transplant Recipients With Posttransplant Erythrocytosis. <i>Artificial Organs</i> , 2009, 33, 1086-1090.	1.9	8
185	Ankaferd Blood Stopper in GI bleeding: alternative for everything?. <i>Gastrointestinal Endoscopy</i> , 2011, 73, 185-186.	1.0	8
186	Ankaferd hemostat for the management of tumoral GI bleeding. <i>Gastrointestinal Endoscopy</i> , 2011, 73, 1072-1073.	1.0	8
187	Dual diverse dynamic reversible actions of Ankaferd on EPCR and PAI-1 inside vascular endothelial cells with and without LPS. <i>Turkish Journal of Haematology</i> , 2011, 29, 361-6.	0.5	8
188	Topical Ankaferd Bloodstopper in the Management of Critical Bleedings due to Hemorrhagic Diathesis. <i>UHOD - Uluslararası Hematoloji-Onkoloji Dergisi</i> , 2011, 21, 160-165.	0.1	8
189	Increased Soluble Selectins as a Reflection of Activated Platelets and Endothelium in Legg-Calve-Perthes Disease. <i>Journal of Pediatric Hematology/Oncology</i> , 2014, 36, e410-e411.	0.6	8
190	Spontaneous subepithelial hemorrhage of renal pelvis and ureter (Antopol-Goldman lesion) in hemophilia A patient with inhibitor. <i>Medicine (United States)</i> , 2020, 99, e20851.	1.0	8
191	Evaluation of Prognostic Significance of the International Staging System According to Glomerular Filtration Rate in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation. <i>Turkish Journal of Haematology</i> , 2021, 38, 33-40.	0.5	8
192	Exposure of Hepatocellular Carcinoma Cells to Ankaferd Blood Stopper® Alters Cell Death Signaling Networks Confirmed by Oncoproteomic and Genomic Profiling Studies. <i>Current Traditional Medicine</i> , 2021, 7, 246-258.	0.4	8
193	A multi-centric study on the efficacy of eltrombopag in management of refractory chronic immune thrombocytopenia. <i>Turkish Journal of Haematology</i> , 2019, 36, 230-237.	0.5	8
194	The impact of early versus late platelet and neutrophil recovery after induction chemotherapy on survival outcomes of patients with acute myeloid leukemia. <i>Turkish Journal of Haematology</i> , 2020, 37, 116-120.	0.5	8
195	Who 2016 Definition of Chronic Myeloid Leukemia and Tyrosine Kinase Inhibitors. <i>Turkish Journal of Haematology</i> , 2020, 37, 42-47.	0.5	8
196	Haemostatic actions of the folkloric medicinal plant extract Ankaferd Blood Stopper. <i>J Int Med Res</i> 2008; 36:163-170. <i>Journal of International Medical Research</i> , 2008, 36, 1447-8; author reply 1448-9.	1.0	8
197	Local Fibrinolysis in Native Arteriovenous Fistulas of Haemodialysis Patients. <i>Blood Purification</i> , 1996, 14, 227-233.	1.8	7
198	Leukoerythroblastosis following the use of G-CSF. , 1996, 52, 123-124.		7

#	ARTICLE	IF	CITATIONS
199	Time to take a healthier view of history. <i>Nature</i> , 1998, 396, 108-108.	27.8	7
200	Myocardial Infarction and Deep Venous Thrombosis in a Young Patient with Behçet Disease. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2006, 12, 105-109.	1.7	7
201	Eculizumab before and after allogeneic hematopoietic stem cell transplantation in a patient with paroxysmal nocturnal hemoglobinuria. <i>Turkish Journal of Haematology</i> , 2011, 28, 223-227.	0.5	7
202	Oral High-Dose Ankaferd Administration Effects on Gastrointestinal System. <i>International Journal of Medical Sciences</i> , 2013, 10, 451-456.	2.5	7
203	Tratamiento efectivo de la hemoptisis mediante aplicaci3n endobronquial del hemost3sico Ankaferd. <i>Archivos De Bronconeumologia</i> , 2014, 50, 407-409.	0.8	7
204	Treatment of pyoderma gangrenosum with thalidomide in a myelodysplastic syndrome case. <i>International Medical Case Reports Journal</i> , 2016, 9, 61.	0.8	7
205	Analysis of the Antiproliferative Effect of Ankaferd Hemostat on Caco-2 Colon Cancer Cells via LC/MS Shotgun Proteomics Approach. <i>BioMed Research International</i> , 2019, 2019, 1-11.	1.9	7
206	The clinical course of COVID-19 in hematopoietic stem cell transplantation (HSCT) recipients. <i>Turkish Journal of Medical Sciences</i> , 2021, 51, 1647-1652.	0.9	7
207	Covid-19 scientific publications from Turkey. <i>Turkish Journal of Medical Sciences</i> , 2021, 51, 877-889.	0.9	7
208	Functional Proteomics of Ankaferd Blood Stopper. <i>Blood</i> , 2008, 112, 4103-4103.	1.4	7
209	CD34+ hematopoietic progenitor cell dose as a predictor of engraftment and survival in multiple myeloma patients undergoing autologous stem cell transplantation. <i>Turkish Journal of Medical Sciences</i> , 2020, 50, 1851-1856.	0.9	7
210	Two cases of extramedullary acute promyelocytic leukemia. <i>Cancer</i> , 1995, 76, 151-152.	4.1	6
211	Tat and pap in hemodialysis patients: Two cats in a bag?. <i>Thrombosis Research</i> , 1995, 80, 447-449.	1.7	6
212	Bulky plasmacytoma of the skull with intracranial involvement. , 1997, 54, 173-173.		6
213	Basic parameters of thrombophilia in ocular Behçet disease with posterior segment involvement. <i>British Journal of Ophthalmology</i> , 2009, 93, 1382-1386.	3.9	6
214	Co-expression of t(15;17) and t(8;21) in a Case of Acute Promyelocytic Leukemia: Review of the Literature. <i>Turkish Journal of Haematology</i> , 2013, 30, 400-404.	0.5	6
215	Generation of Chimeric "ABS Nanoheostat" Complex and Comparing Its Histomorphological In Vivo Effects to the Traditional Ankaferd Hemostat in Controlled Experimental Partial Nephrectomy Model. <i>International Journal of Biomaterials</i> , 2013, 2013, 1-10.	2.4	6
216	Local Renin-Angiotensin System in Normal Hematopoietic and Multiple Myeloma-Related Progenitor Cells. <i>Turkish Journal of Haematology</i> , 2014, 31, 136-142.	0.5	6

#	ARTICLE	IF	CITATIONS
217	High iron content of Ankaferd hemostat as a clue for its hemostatic action of red blood cell origin. Blood Coagulation and Fibrinolysis, 2015, 26, 233-234.	1.0	6
218	Outcomes with frontline nilotinib treatment in Turkish patients with newly diagnosed Philadelphia chromosomeâ€“positive chronic myeloid leukemia in chronic phase. Expert Opinion on Pharmacotherapy, 2016, 17, 1851-1858.	1.8	6
219	The impact of At1r inhibition via losartan on the anti-leukaemic effects of doxorubicin in acute myeloid leukaemia. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2019, 20, 147032031985131.	1.7	6
220	The impact of JAK/STAT inhibitor ruxolitinib on the genesis of lymphoproliferative diseases. Turkish Journal of Medical Sciences, 2019, 49, 661-674.	0.9	6
221	Effects of Ankaferd Hemostat on Helicobacter pylori strains and antibiotic resistance. Turkish Journal of Medical Sciences, 2019, 49, 347-355.	0.9	6
222	Impact of Time Between Induction Chemotherapy and Complete Remission on Survival Outcomes in Patients With Acute Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 729-734.	0.4	6
223	Predictive factors for stem cell mobilization failure in multiple myeloma patients: A single center experience. Transfusion and Apheresis Science, 2020, 59, 102595.	1.0	6
224	Leukemic stem cells shall be searched in the bone marrow before â€œtyrosine kinase inhibitorâ€“discontinuationâ€“in chronic myeloid leukemia. International Journal of Laboratory Hematology, 2021, 43, 1110-1116.	1.3	6
225	The significance and distinct interactions of various growth factors in physiologic and pathologic megakaryocytopoiesis/thrombocytopoiesis. Australian and New Zealand Journal of Medicine, 1997, 27, 191-192.	0.5	5
226	Piebaldism associated with congenital dyserythropoietic anemia type II (HEMPAS). American Journal of Hematology, 2002, 69, 210-213.	4.1	5
227	Bone Marrow and Peripheral Blood C-kit Ligand Concentrations in Patients with Thrombocytosis and Thrombocytopenia. Hematology, 2003, 8, 369-373.	1.5	5
228	Effect of platelet count on secretion capacity: formulization and use of the formulae for evaluation of platelet secretion in thrombocytopenic patients. Blood Coagulation and Fibrinolysis, 2008, 19, 633-637.	1.0	5
229	Interleukinâ€“1 Î² and interleukinâ€“6 in clonal versus reactive thrombocytosis. European Journal of Haematology, 1995, 55, 339-340.	2.2	5
230	An alternative hemostatic method for early GI bleeding caused by anastomotic ulcer. Gastrointestinal Endoscopy, 2010, 72, 902-903.	1.0	5
231	A Comparison of Jurkat Cell-Reactive Anti-T Lymphocyte Globulin and Fetal Anti-Thymocyte Globulin Preparations in the Treatment of Aplastic Anemia. Medical Principles and Practice, 2011, 20, 341-344.	2.4	5
232	Angiotensin Converting Enzyme Insertion/Deletion Gene Polymorphisms in Leukemic Hematopoiesis. UHOD - Uluslararası Hematoloji-Onkoloji Dergisi, 2011, 21, 1-9.	0.1	5
233	Short-Term Effects of Ankaferd Hemostat for Renal Artery Embolization: An Experimental Study. Cardiovascular and Interventional Radiology, 2013, 36, 498-504.	2.0	5
234	Current Management of Chronic Myeloid Leukemia with Tyrosine Kinase Inhibitors. Turkish Journal of Haematology, 2013, 30, 247-255.	0.5	5

#	ARTICLE	IF	CITATIONS
235	Effective Management of Hemoptysis Via Endobronchial Application of Ankaferd Hemostat. <i>Archivos De Bronconeumologia</i> , 2014, 50, 407-409.	0.8	5
236	Clinical and pathological correlations of marrow PUMA and P53 expressions in myelodysplastic syndromes. <i>Apmis</i> , 2015, 123, 445-451.	2.0	5
237	Discontinuation of imatinib mesylate could improve renal impairment in chronic myeloid leukemia. <i>Open Medicine (Poland)</i> , 2018, 14, 22-24.	1.3	5
238	Frontline nilotinib treatment in Turkish patients with Philadelphia chromosome-“positive chronic Myeloid Leukemia in chronic phase: updated results with 2 years of follow-up. <i>Hematology</i> , 2018, 23, 771-777.	1.5	5
239	A unique case of complex variant translocation of t(6;9;22)(p22;q34;q11.2), der(19) in a newly diagnosed patient with chronic myeloid leukemia. <i>Cancer Genetics</i> , 2019, 237, 78-81.	0.4	5
240	Mitoxantrone-melphalan conditioning regimen for autologous stem cell transplantation in relapsed/refractory lymphoma. <i>Turkish Journal of Medical Sciences</i> , 2019, 49, 985-992.	0.9	5
241	Efficacy and Feasibility of Allogeneic Hematopoietic Stem-Cell Transplantation in the Treatment of Refractory Acute Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 177-182.	0.4	5
242	Allogeneic Hematopoietic Stem-Cell Transplantation Improves Disease-Free Survival Compared to Pediatric-Inspired Berlin-Frankfurt-Münster Chemotherapy in Adult Acute Lymphoblastic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 147-153.	0.4	5
243	Protein Kinases in Hematological Disorders. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1275, 383-393.	1.6	5
244	Pharmacobiological Approach for the Clinical Development of Ruxolitinib in Myeloproliferative Neoplasms. <i>Turkish Journal of Haematology</i> , 2015, 32, 163-167.	0.5	5
245	Comparison of Myeloablative Versus Reduced-Intensity Conditioning Regimens for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia: A Cohort Study. <i>Turkish Journal of Haematology</i> , 2019, 36, 88-96.	0.5	5
246	The factors affecting early death after the initial therapy of acute myeloid leukemia. <i>International Journal of Clinical and Experimental Medicine</i> , 2015, 8, 22564-9.	1.3	5
247	Possible cytokine mechanism of increased megakaryocytic proliferation in 5q- syndrome. <i>American Journal of Hematology</i> , 1996, 52, 124-124.	4.1	4
248	Autoimmune hemolytic anemia in Philadelphia positive chronic myeloid leukemia with t(7;14) anomaly after 5 years of interferon alpha treatment. <i>Haematologia</i> , 2002, 32, 163-167.	0.3	4
249	Plasma Thrombospondin in Immune Thrombocytopenic Purpura. <i>Journal of International Medical Research</i> , 2002, 30, 52-55.	1.0	4
250	Protein C Inhibitor and Serum Amyloid a in Immune Thrombocytopaenic Purpura. <i>Journal of International Medical Research</i> , 2004, 32, 62-65.	1.0	4
251	Increased serum thrombopoietin concentration in systemic sclerosis associated with myelofibrosis and thrombocytosis. <i>Joint Bone Spine</i> , 2006, 73, 122-123.	1.6	4
252	The adhesion molecules of L-selectin and ICAM-1 in thrombocytosis and thrombocytopenia. <i>Platelets</i> , 2010, 21, 49-52.	2.3	4

#	ARTICLE	IF	CITATIONS
253	Basic Hemostatic Parameters in Patients with Long-Term Oral Anticoagulation Undergoing Cholecystectomy. <i>Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A</i> , 2011, 21, 417-425.	1.0	4
254	A Placebo-Controlled, Randomized, Double-Blinded, Cross-Over Phase-I Clinical Study Indicating the Safety of Topical Ankaferd Hemostat in Healthy Volunteers. <i>UHOD - Uluslararası Hematoloji-Onkoloji Dergisi</i> , 2012, 22, 267-274.	0.1	4
255	Evaluation of the mean platelet volume in secondary amyloidosis due to familial Mediterranean fever. <i>Rheumatology International</i> , 2013, 33, 2555-2559.	3.0	4
256	The therapeutic goals of essential thrombocythemia under the clouds of over-treatment and under-treatment. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 1431-1436.	1.8	4
257	The Impact of Eltrombopag Administration on the Clinical Course of Severe Refractory Fatal Acquired Aplastic Anemia. <i>Turkish Journal of Haematology</i> , 2013, 30, 328-330.	0.5	4
258	Severe radiation esophagitis successfully treated with Ankaferd hemostat. <i>Gastrointestinal Endoscopy</i> , 2015, 81, 1048-1049.	1.0	4
259	Indications and outcomes of splenectomy for hematological disorders. <i>Open Medicine (Poland)</i> , 2019, 14, 491-496.	1.3	4
260	Ghosal hematodiaphyseal dysplasia with autoimmune anemia in two adult siblings. <i>Transfusion and Apheresis Science</i> , 2019, 58, 449-452.	1.0	4
261	Effects of Ankaferd Hemostat on red blood cell aggregation: a hemorheological study. <i>Turkish Journal of Medical Sciences</i> , 2019, 49, 356-360.	0.9	4
262	Antiinfective and wound-healing pleiotropic actions of Ankaferd hemostat. <i>Turkish Journal of Medical Sciences</i> , 2020, 50, 1434-1435.	0.9	4
263	Pharmacobiological management of hemostasis within clinical backgrounds via Ankaferd hemostat (Ankaferd blood stopper). <i>SAGE Open Medicine</i> , 2020, 8, 205031212090781.	1.8	4
264	Four-Dimensional Echocardiographic Evaluation of Left Ventricular Systolic Functions in Patients with Chronic Myeloid Leukaemia Receiving Tyrosine Kinase Inhibitors. <i>Cardiovascular Toxicology</i> , 2021, 21, 216-223.	2.7	4
265	Perspectives for immune plasma treatment of COVID-19. <i>Turkish Journal of Medical Sciences</i> , 2021, 51, 1-9.	0.9	4
266	Ankaferd hemostat: from molecules to medicine. <i>Turkish Journal of Medical Sciences</i> , 2020, 50, 1739-1750.	0.9	4
267	Comparison of Myelodysplastic Syndrome Prognostic Scoring Systems. <i>Turkish Journal of Haematology</i> , 2016, 33, 119-126.	0.5	4
268	Antibacterial Activities of Ankaferd Hemostat (ABS) on Shiga Toxin-Producing <i>Escherichia coli</i> and Other Pathogens Significant in Foodborne Diseases. <i>Turkish Journal of Haematology</i> , 2017, 34, 93-98.	0.5	4
269	Splenic artery embolization with Ankaferd blood stopper in a sheep model. <i>Diagnostic and Interventional Radiology</i> , 2016, 22, 354-357.	1.5	4
270	On Being a "Physician Patient"™ With His Own Experimental Therapeutic Drug. <i>Turkish Journal of Haematology</i> , 2018, 35, 302-303.	0.5	4

#	ARTICLE	IF	CITATIONS
271	Evaluation of a haemostatic agent in rabbits. African Journal of Traditional Complementary and Alternative Medicines, 2011, 8, 61-5.	0.2	4
272	Clinical variations between three different causes of thrombocytopenia. Nigerian Journal of Clinical Practice, 2021, 24, 17.	0.6	4
273	Coagulation and Fibrinolysis in Amyloid and Non-amyloid Hemodialysis Patients: Assessment of Local Hemostatic Kinetics Within Arteriovenous Fistulas. Clinical and Applied Thrombosis/Hemostasis, 1996, 2, 279-284.	1.7	3
274	Thrombosis and Hemorrhage in Chronic Myeloproliferative Disorders. Clinical and Applied Thrombosis/Hemostasis, 1999, 5, 282-284.	1.7	3
275	Lack of Platelet Activation Reflected by Circulating Soluble Glycoprotein V in Pre-eclampsia. Journal of International Medical Research, 2007, 35, 704-708.	1.0	3
276	Alterations of von Willebrand Factor and Ristocetin Cofactor Activity During Atrial Fibrillation. Clinical and Applied Thrombosis/Hemostasis, 2009, 15, 103-108.	1.7	3
277	Do All Hemolytic Anemias That Occur After Mitral Valve Repair Require Surgical Treatment?. Clinical Cardiology, 2010, 33, E76-8.	1.8	3
278	Controlling of upper gastrointestinal bleeding associated with severe immune thrombocytopenia via topical adjunctive application of Ankaferd blood stopper. Blood Coagulation and Fibrinolysis, 2012, 23, 464.	1.0	3
279	In Vivo Healing Effects of Ankaferd Blood Stopper on the Residual Pancreatic Tissue in a Swine Model of Distal Pancreatectomy. Indian Journal of Surgery, 2015, 77, 176-181.	0.3	3
280	Ultrastructural analyses of the novel chimeric hemostatic agent generated via nanotechnology, ABS nanohemostat, at the renal tissue level. SpringerPlus, 2016, 5, 1931.	1.2	3
281	Effect of postremission high dose cytarabine-based consolidation chemotherapy before allogeneic stem cell transplantation in outcomes of acute myeloid leukemia patients. Transfusion and Apheresis Science, 2018, 57, 752-755.	1.0	3
282	Unclassifiable non-CML classical myeloproliferative diseases with microcytosis: findings indicating diagnosis of polycythemia vera masked by iron deficiency. Turkish Journal of Medical Sciences, 2019, 49, 1560-1563.	0.9	3
283	Ankaferd hemostat (ABS) as a potential mucosal topical agent for the management of COVID-19 syndrome based on its PAR-1 inhibitory effect and oestrogen content. Medical Hypotheses, 2020, 143, 110150.	1.5	3
284	Immunogenomic phases of COVID-19 and appropriate clinical management. Lancet Microbe, The, 2020, 1, e278.	7.3	3
285	Could Targeting HMGB1 be Useful for the Clinical Management of COVID-19 Infection?. Combinatorial Chemistry and High Throughput Screening, 2021, 24, 587-590.	1.1	3
286	Lipotoxicity-Related Hematological Disorders in Obesity. Advances in Experimental Medicine and Biology, 2017, 960, 469-487.	1.6	3
287	Haemostatic Actions of the Folkloric Medicinal Plant Extract, Ankaferd Blood Stopper.. Blood, 2007, 110, 3943-3943.	1.4	3
288	Evaluation of Anti-Neoplastic Effects of a New Hemostatic Agent Ankaferd Blood Stopper on Myeloma Cell Line and Plasmocytoma Development in Balb/c Mice: Results of the First in Vitro and in Vivo Study. Blood, 2014, 124, 5728-5728.	1.4	3

#	ARTICLE	IF	CITATIONS
289	The Prognosis of Adult Burkitt's Cell Leukemia in Real-Life Clinical Practice. Turkish Journal of Haematology, 2016, 33, 281-285.	0.5	3
290	The Effect of Chronic Angiotensin Converting Enzyme Inhibition on Circulating Prolactin in Systemic Hypertension. Hormone and Metabolic Research, 1994, 26, 491-493.	1.5	2
291	Haemostatic markers in amyloid vs non-amyloid uraemic patients on maintenance haemodialysis. Nephrology, 1996, 2, 273-277.	1.6	2
292	Behçet's disease as a prethrombotic state. International Journal of Clinical and Laboratory Research, 1998, 28, 200-200.	1.0	2
293	Could Serum Haptoglobin Concentration Be Used as a Marker of Hypersplenism in Chronic Liver Disease?. American Journal of Gastroenterology, 1998, 93, 2641-2642.	0.4	2
294	Lack of Association between familial Mediterranean fever and Angiotensin converting enzyme gene polymorphism. Joint Bone Spine, 2006, 73, 334-336.	1.6	2
295	Soluble Platelet Glycoprotein V in Distinct Disease States of Pathological Thrombopoiesis. Journal of the National Medical Association, 2008, 100, 86-90.	0.8	2
296	Striking Promotion of the in vitro Myeloma Monoclonal Immunoglobulin Aggregation by Ankaferd Hemostat. UHOD - Uluslararası Hematoloji-Onkoloji Dergisi, 2012, 22, 15-22.	0.1	2
297	High frequency of autonomous T-cell proliferation compatible with T-cell large granular lymphocytic leukemia in patients with cytopenia of unknown etiology. International Journal of Hematology, 2015, 102, 211-217.	1.6	2
298	Molecular Basis of Ankaferd-Induced Hemostasis in the Management of Sternal Bleeding. Heart Surgery Forum, 2012, 15, E305-E305.	0.5	2
299	Expression Profiles of the Individual Genes Corresponding to the Genes Generated by Cytotoxicity Experiments with Bortezomib in Multiple Myeloma. Turkish Journal of Haematology, 2016, 33, 286-292.	0.5	2
300	Sole Infrequent Karyotypic Aberration Trisomy 6 in a Patient with Acute Myeloid Leukemia and Breast Cancer in Remission. Turkish Journal of Haematology, 2017, 34, 103-104.	0.5	2
301	TUMOR LYSIS SYNDROME DUE TO TARGETING OF HEPATOCELLULAR CARCINOMA ASSOCIATED WITH CHRONIC MYELOMONOCYTIC LEUKEMIA. Turkish Journal of Haematology, 2019, 36, 218-219.	0.5	2
302	Effects of Smoking on Hematological Parameters and Ferritin Levels. Haseki Tip Bulteni, 2019, 57, 372-376.	0.3	2
303	Haematopoietic Cytokines and Increased Megakaryocytic Proliferation in Chromosome 5q Deletion. Acta Haematologica, 1997, 97, 244-244.	1.4	1
304	The prethrombotic/hypercoagulable state of Behçet's disease: Comment on the article by Golden et al. Arthritis and Rheumatism, 1997, 40, 1915-1916.	6.7	1
305	Ischemic heart disease in Behçet's syndrome. Rheumatology International, 1998, 17, 251-251.	3.0	1
306	Pseudospontaneous Platelet Aggregation and Spuriously Elevated Blood Cell Counts in Cryoglobulinemia. Clinical and Applied Thrombosis/Hemostasis, 1998, 4, 209-212.	1.7	1

#	ARTICLE	IF	CITATIONS
307	Effects of Extracorporeal Circulation on Thrombin-Antithrombin III and Prothrombin Fragment 1+2 Levels. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2002, 8, 61-63.	1.7	1
308	Proinflammatory and Hematopoietic Cytokines in Reactive and Clonal Thrombocytosis. <i>Southern Medical Journal</i> , 2002, 95, 565-566.	0.7	1
309	Plasma Thrombopoietin in Patients With Cavernous Transformation of the Portal Vein. <i>International Journal of Hematology</i> , 2002, 75, 91-94.	1.6	1
310	Unchanged global fibrinolytic capacity during the course of hematopoietic stem cell transplantation. <i>Blood Coagulation and Fibrinolysis</i> , 2006, 17, 47-51.	1.0	1
311	Histopathological Alterations in the Kidney Tissue Following Topical Ankaferd Hemostat Application in a Rat Renal Injury Model. <i>UHOD - Uluslararası Hematoloji-Onkoloji Dergisi</i> , 2012, 22, 275-281.	0.1	1
312	The Clinical Impact of Low Doses of Dasatinib in Patients with Chronic Myeloid Leukemia. <i>UHOD - Uluslararası Hematoloji-Onkoloji Dergisi</i> , 2012, 22, 8-14.	0.1	1
313	Effective Molecular Monitoring and the Proper Management of Pleural Effusion During the First-Line Dasatinib Administration in CML. <i>UHOD - Uluslararası Hematoloji-Onkoloji Dergisi</i> , 2012, 22, 1-7.	0.1	1
314	Echocardiographic Dilemma: Misleading Thrombus Appearance Due to Cavitation With Intravascular Hemolysis on a Mechanical Prosthetic Valve. <i>Canadian Journal of Cardiology</i> , 2013, 29, 403.e1-403.e2.	1.7	1
315	Long-Term Sustained Hemorrhage Due to Bone Marrow Biopsy Successfully Treated With Topical Ankaferd Hemostat in a Bleeding-Prone Patient With Secondary Amyloidosis. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2013, 19, 338-340.	1.7	1
316	Next Generation Nanomedicine in the Genesis of "Ankaferd Blood Stopper Nanohemostat". <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2014, 20, 456-457.	1.7	1
317	Peripheral FLT-3 ligand levels as a pathobiological parameter during the clinical course of acute myeloid leukemia. <i>Turkish Journal of Medical Sciences</i> , 2016, 46, 1889-1893.	0.9	1
318	Reply. <i>Annals of Pharmacotherapy</i> , 2016, 50, 336-336.	1.9	1
319	The Modelled Effectiveness of Ruxolitinib on Survival in Polycythemia Patients with Hydroxyurea Resistance/Intolerance in Turkey. <i>Value in Health</i> , 2017, 20, A545.	0.3	1
320	Epidemiological Estimates and Treatment Practice Pattern in Polycythemia Vera Patients in Turkey: Results Based on an Expert Panel. <i>Value in Health</i> , 2017, 20, A546.	0.3	1
321	The Antithrombin Effect of Ankaferd Hemostat (ABS) Is Related to the High Iron Content of the Medicine. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2019, 25, 107602961882441.	1.7	1
322	The comparison of bone marrow kinetics between patients with acute myeloid leukemia and acute promyelocytic leukemia after induction chemotherapy. <i>Immunopharmacology and Immunotoxicology</i> , 2020, 42, 17-21.	2.4	1
323	Comparison of bortezomib-cyclophosphamide-dexamethasone versus bortezomib-dexamethasone based regimens in newly diagnosed multiple myeloma patients. <i>Hematology Reports</i> , 2020, 12, 8267.	0.8	1
324	Long-term results of allogeneic peripheral blood hematopoietic stem cell transplantation for severe aplastic anemia. <i>Transfusion and Apheresis Science</i> , 2021, 60, 103050.	1.0	1

#	ARTICLE	IF	CITATIONS
325	Current community transmission and future perspectives on the COVID-19 process. Turkish Journal of Medical Sciences, 2021, 51, 1001-1011.	0.9	1
326	Antitumor activity of Ankaferd Blood Stopper® on MCF-7 breast cancer: A proteomic approach to ascertain the mechanism of the action. Journal of Herbal Medicine, 2021, 28, 100449.	2.0	1
327	Experience With BFM 95 Pediatric Regimen In Adult ACUTE Lymphoblastic Leukemia. Blood, 2013, 122, 5015-5015.	1.4	1
328	Massive Life-Threatening Hemorrhages Due to Toxic Oral Intake of 3750 Mg Dabigatran Etexilate As a Suicide Attempt and the Clinical Management. Blood, 2014, 124, 5091-5091.	1.4	1
329	Endothelial Cells, Ankaferd Hemostat, and Estradiol. Turkish Journal of Haematology, 2016, 33, 261-262.	0.5	1
330	The Management of Chronic Myeloid Leukemia in the Era of Second Generation Tyrosine Kinase Inhibitors. UHOD - Uluslararası Hematoloji-Onkoloji Dergisi, 2016, 26, 1-3.	0.1	1
331	COVID-19, Renin-angiotensin System and Hematopoiesis. Turkish Journal of Haematology, 2020, 37, 207-208.	0.5	1
332	Clinicopathological associations of acquired erythroblastopenia. International Journal of Clinical and Experimental Medicine, 2015, 8, 22515-9.	1.3	1
333	Evisceration of the Eye in a Renal Transplant Recipient with Cytomegalovirus Chorioretinitis. American Journal of Nephrology, 1996, 16, 367-368.	3.1	0
334	Extramedullary acute promyelocytic leukemia. Cancer, 1997, 80, 514-521.	4.1	0
335	Hemostatic Problems in Uremia. Blood Purification, 1998, 16, 220-221.	1.8	0
336	Thrombosis Involving the Major Veins with Heterozygote Factor V Leiden Mutation as the Only Risk Factor. Clinical and Applied Thrombosis/Hemostasis, 1999, 5, 187-189.	1.7	0
337	Absence d'association entre l'hypermétrie méditerranéenne familiale et le polymorphisme du gène de l'enzyme de conversion de l'angiotensine. Revue Du Rhumatisme (Edition Française), 2006, 73, 523-525.	0.0	0
338	Chemotherapy and imatinib-induced molecular remission in lymphoid blast crisis after 20 years of untreated chronic myeloid leukemia. American Journal of Hematology, 2007, 82, 333-333.	4.1	0
339	Unusual Extramedullary Recurrence and Renal Relapse Despite Complete Chimerysm after Allografting in Ph+ ALL. UHOD - Uluslararası Hematoloji-Onkoloji Dergisi, 2012, 22, 46-50.	0.1	0
340	Topical Ankaferd hemostat for the management of clinical bleeding plus hemorrhagic diathesis. Gastrointestinal Intervention, 2013, 2, 127.	0.1	0
341	Key Decision Just After 3 Months Following TKI Initiation in CML: Better and not Difficult. UHOD - Uluslararası Hematoloji-Onkoloji Dergisi, 2013, 23, 1-2.	0.1	0
342	Authors' response to the comments on automated platelet analyses by Dr Beyan. Journal of Cardiology, 2014, 63, 244-245.	1.9	0

#	ARTICLE	IF	CITATIONS
343	Melanonychia Secondary to Long-Term Treatment with Hydroxycarbamide: An Essential Thrombocytosis Case. <i>Case Reports in Hematology</i> , 2015, 2015, 1-3.	0.4	0
344	Tryptophan in Molecular Hematopoiesis. <i>Molecular and Integrative Toxicology</i> , 2015, , 253-267.	0.5	0
345	Efficacy and safety of ruxolitinib in patients with myelofibrosis: a retrospective and multicenter experience in Turkey. <i>Turkish Journal of Medical Sciences</i> , 2021, 51, 1033-1042.	0.9	0
346	Free Health Coverage for All COVID-19 Patients is Required to Defeat the Virus at The Community Level. <i>Acta Medica</i> , 2021, 52, 90-91.	0.2	0
347	Use Of Nilotinib As a First Line Treatment In Adult Patients With Philadelphia Chromosome-Positive and Chronic Phase Myeloid Leukemia. <i>Blood</i> , 2013, 122, 2742-2742.	1.4	0
348	Cytokines, Thrombopoietin, and Selectins in Immune Thrombocytopenic Purpura. , 1999, , 213-216.		0
349	High-dose chemotherapy and autologous peripheral blood stem cell (PBSC) transplantation with non-cryopreserved PBSCs in multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2014, 32, e19577-e19577.	1.6	0
350	Lower Doses of Plerixafor Use Is Sufficient to Effectively Mobilize PBSC (Peripheral Blood) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 462 Td (1.4	0
351	Rebound Thrombocytosis Is an Independent Predictor of Good Prognosis in AML Patients Attaining First Complete Remission. <i>Blood</i> , 2014, 124, 2283-2283.	1.4	0
352	Nilotinib Results in Improved Rates of Molecular Response in Turkish Newly Diagnosed CML-CP Patients: A 24-Month Update. <i>Blood</i> , 2014, 124, 5532-5532.	1.4	0
353	Prognostic Factors for Survival of Elderly Patients with Acute Myeloid Leukemia after Intensive Chemotherapy: Validation of 3 Popular Prognostic Models. <i>Blood</i> , 2014, 124, 5332-5332.	1.4	0
354	Long-Term Results of Non- Fludarabine Versus Fludarabine-Based Conditioning Regimens in Severe Aplastic Anemia Patients. <i>Blood</i> , 2018, 132, 5700-5700.	1.4	0
355	Waldenstrom macroglobulinemia presenting as plasma cell leukemia associated with hyperviscosity syndrome. <i>Medical Science and Discovery</i> , 0, , 390-392.	0.1	0
356	Aggressive Clinicopathological Course of Myeloma with t(3;16) (q21;q22) Cytogenetic Abnormality. <i>Turkish Journal of Haematology</i> , 2019, 36, 62-63.	0.5	0
357	Thrombosis and Bleeding in Philadelphia Negative Myeloproliferative Neoplasia: Incidences and Risk Factors. <i>Acta Medica</i> , 2019, 50, 1-7.	0.2	0
358	Retrospective evaluation of chromosome 1 anomalies in hematologic malignancies: A single center study. <i>Genetics & Applications</i> , 2019, 3, 17.	0.1	0
359	Prophylactic Central Nervous System Irradiation Is Not Indispensable In Adult Patients With Acute Lymphoblastic Leukemia: A Multi-Center Retrospective Cohort Study. <i>Turkish Journal of Haematology</i> , 2022, , .	0.5	0
360	Title is missing!. , 2020, 15, e0242497.		0

#	ARTICLE	IF	CITATIONS
361	Title is missing!. , 2020, 15, e0242497.		0
362	Title is missing!. , 2020, 15, e0242497.		0
363	Title is missing!. , 2020, 15, e0242497.		0
364	Title is missing!. , 2020, 15, e0242497.		0
365	Title is missing!. , 2020, 15, e0242497.		0
366	Title is missing!. , 2020, 15, e0242497.		0
367	Title is missing!. , 2020, 15, e0242497.		0
368	Bone Marrow Origin of Coronary Artery Diseases: The Impact of the Local Renin-Angiotensin System.. Acta Cardiologica Sinica, 2022, 38, 13-20.	0.2	0
369	Event-free Survival in Patients with Chronic Myeloid Leukemia Receiving Front-line Imatinib Mesylate. Acta Medica, 0, , .	0.2	0
370	Turkey real-life data: demographic features, treatment results and effects of comorbidities in chronic myeloid leukemia. International Journal of Hematologic Oncology, 0, , .	1.6	0